Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation

References

• Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016 Jul;4(4):565–572. doi: 10.1016/j.jaip.2016.04.012
   PubMed Web of Science ®Google Scholar
• Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy. 2017 Feb;72(2):274–281. doi: 10.1111/all.13042
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1–464. doi: 10.4193/Rhin20.401
   Google Scholar
• Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017 Jan 24;12(1):331–357. doi: 10.1146/annurev-pathol-052016-100401
   PubMedGoogle Scholar
• Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021 Mar;11(3):213–739. doi: 10.1002/alr.22741
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Gao Y, et al. Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma. Rhinology. 2020 Apr 1;58(2):126–135. doi: 10.4193/Rhin19.184
   PubMed Web of Science ®Google Scholar
• Loftus CA, Soler ZM, Koochakzadeh S, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020 Feb;10(2):199–207. doi: 10.1002/alr.22487
   PubMed Web of Science ®Google Scholar
• Miglani A, Divekar RD, Azar A, et al. Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype. Int Forum Allergy Rhinol. 2018 Sep;8(9):1047–1051. doi: 10.1002/alr.22146
   PubMed Web of Science ®Google Scholar
• DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017 Mar;127(3):550–555. doi: 10.1002/lary.26391
   PubMed Web of Science ®Google Scholar
• Lou H, Meng Y, Piao Y, et al. Cellular phenotyping of chronic rhinosinusitis with nasal polyps. Rhinology. 2016 Jun;54(2):150–159. doi: 10.4193/Rhino15.271
   PubMed Web of Science ®Google Scholar
• Longino ES, Labby AB, Wu J, et al. Association of cytokine profile with prior treatment failure and revision surgery in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2023 Jan;13(1):5–14. doi: 10.1002/alr.23035
   PubMed Web of Science ®Google Scholar
• Aguiar C, Valente P, Medeiros N, et al. Predictive factors of revision endoscopic sinus surgery. Eur Arch Otorhinolaryngol. 2023 Feb 10;280(7):3265–3269. doi: 10.1007/s00405-023-07856-7
   PubMed Web of Science ®Google Scholar
• Bayer K, Hamidovic S, Brkic FF, et al. Peripheral eosinophil count and eosinophil-to-lymphocyte ratio are associated with revision sinus surgery. Eur Arch Otorhinolaryngol. 2023 Jan;280(1):183–190. doi: 10.1007/s00405-022-07497-2
   PubMed Web of Science ®Google Scholar
• Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022 May;149(5):1491–1503. doi: 10.1016/j.jaci.2022.02.016
   PubMed Web of Science ®Google Scholar
• Wang C, Yan B, Zhang L. The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2020 Mar;16(3):293–310. doi: 10.1080/1744666X.2020.1723417
   PubMed Web of Science ®Google Scholar
• Kucuksezer UC, Ozdemir C, Akdis M, et al. Chronic rhinosinusitis: pathogenesis, therapy options, and more. Expert Opin Pharmacother. 2018 Nov;19(16):1805–1815. doi: 10.1080/14656566.2018.1527904
   PubMed Web of Science ®Google Scholar
• Ozdemir C. Monoclonal antibodies in allergy; updated applications and promising trials. Recent Pat Inflamm Allergy Drug Discov. 2015;9(1):54–65. doi: 10.2174/1872213X09666150223115303
   PubMedGoogle Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209):1638–1650. doi: 10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020 Sep;146(3):595–605. doi: 10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Oct;9(10):1141–1153. doi: 10.1016/S2213-2600(21)00097-7
   PubMed Web of Science ®Google Scholar
• Xu X, Reitsma S, Wang Y, et al. Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease. Allergy. 2022 Dec;77(12):3593–3605. doi: 10.1111/all.15507
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016 Feb 2;315(5):469–479. doi: 10.1001/jama.2015.19330
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan B, Shen S, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul;61:102076. doi: 10.1016/j.eclinm.2023.102076
   PubMedGoogle Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013 Jan;131(1):110–6 e1. doi: 10.1016/j.jaci.2012.07.047
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011 Nov;128(5):989-95 e1–8. doi: 10.1016/j.jaci.2011.07.056
   Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017 Oct;140(4):1024–1031 e14. doi: 10.1016/j.jaci.2017.05.044
   PubMed Web of Science ®Google Scholar
• Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021 Jun;51(6):836–844. doi: 10.1111/cea.13852
   PubMed Web of Science ®Google Scholar
• Takabayashi T, Asaka D, Okamoto Y, et al. A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis. Am J Rhinol Allergy. 2021 Nov;35(6):861–870. doi: 10.1177/19458924211009429
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022 Apr;149(4):1309–1317 e12. doi: 10.1016/j.jaci.2021.08.030
   PubMed Web of Science ®Google Scholar
• Lalani T, Simmons RK, Ahmed AR. Biology of IL-5 in health and disease. Ann Allergy Asthma Immunol. 1999 Apr;82(4):317-32; quiz 332–3. doi: 10.1016/S1081-1206(10)63281-4
   Web of Science ®Google Scholar
• Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009 Dec;21(12):1303–1309. doi: 10.1093/intimm/dxp102
   PubMed Web of Science ®Google Scholar
• Gevaert P, Han JK, Smith SG, et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022 Nov;12(11):1413–1423. doi: 10.1002/alr.22994
   PubMed Web of Science ®Google Scholar
• Rosati D, Rosato C, Pagliuca G, et al. Predictive markers of long-term recurrence in chronic rhinosinusitis with nasal polyps. Am J Otolaryngol. 2020 Jan;41(1):102286. doi: 10.1016/j.amjoto.2019.102286
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016 May;137(5):1449–1456 e4. doi: 10.1016/j.jaci.2015.12.1324
   PubMed Web of Science ®Google Scholar
• Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Ralpha axis, and the biologic effects of benralizumab in severe asthma. Respir med. 2019 Nov;160:105819. doi: 10.1016/j.rmed.2019.105819
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):1344–1353 e2. doi: 10.1016/j.jaci.2010.04.004
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Ralpha inhibition with dupilumab. Expert Rev Clin Immunol. 2020 Dec;16(12):1115–1125. doi: 10.1080/1744666X.2021.1847083
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023 Jun 1;61(3):194–202. doi: 10.4193/Rhin22.489
   PubMed Web of Science ®Google Scholar
• Venge P, Bystrom J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999 Sep;29(9):1172–1186. doi: 10.1046/j.1365-2222.1999.00542.x
   PubMed Web of Science ®Google Scholar
• Mortuaire G, Gengler I, Carpentier C, et al. T helper 2 inflammatory markers are associated with recurrence in chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery. Rhinology. 2020 Oct 1;58(5):444–450. doi: 10.4193/Rhin19.439
   PubMed Web of Science ®Google Scholar
• Van Zele T, Holtappels G, Gevaert P, et al. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014 May;28(3):192–198. doi: 10.2500/ajra.2014.28.4033
   PubMed Web of Science ®Google Scholar
• Singh D, Fuhr R, Bird NP, et al. A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702–712. doi: 10.1111/bcp.15002
   PubMed Web of Science ®Google Scholar
• Hong H, Liao S, Chen F, et al. Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation. Allergy. 2020 Nov;75(11):2794–2804. doi: 10.1111/all.14526
   PubMed Web of Science ®Google Scholar
• Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023 Jan;23(1):24–37. doi: 10.1038/s41577-022-00735-y
   PubMed Web of Science ®Google Scholar
• Kato A. Group 2 innate lymphoid cells in airway Diseases. Chest. 2019 Jul;156(1):141–149. doi: 10.1016/j.chest.2019.04.101
   PubMed Web of Science ®Google Scholar
• Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013 Sep;132(3):593–600 e12. doi: 10.1016/j.jaci.2013.04.005
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Fan E, Li Y, et al. Clinical characteristics and expression of thymic stromal lymphopoetin in eosinophilic and non-eosinophilic chronic rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2013;75(1):37–45. doi: 10.1159/000346929
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tezepelumab: first approval. Drugs. 2022 Mar;82(4):461–468. doi: 10.1007/s40265-022-01679-2
   PubMed Web of Science ®Google Scholar
• Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Nov;9(11):1299–1312. doi: 10.1016/S2213-2600(21)00226-5
   PubMed Web of Science ®Google Scholar
• Favier V, Charriot J, Crampette L, et al. What place will tezepelumab hold in the treatment paradigm in chronic rhinosinusitis? Expert Rev Clin Immunol. 2023 May;21:1–5.
   Google Scholar
• Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther. 2009 Jun;11(3):329–336.
   PubMedGoogle Scholar
• Markham A. Reslizumab: first global approval. Drugs. 2016 May;76(8):907–911. doi: 10.1007/s40265-016-0583-2
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006 Nov;118(5):1133–1141. doi: 10.1016/j.jaci.2006.05.031
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005 Nov;23(5):479–490. doi: 10.1016/j.immuni.2005.09.015
   PubMed Web of Science ®Google Scholar
• Drake LY, Kita H. IL-33: biological properties, functions, and roles in airway disease. Immunol Rev. 2017 Jul;278(1):173–184. doi: 10.1111/imr.12552
   PubMed Web of Science ®Google Scholar
• Rank MA, Kobayashi T, Kozaki H, et al. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009 May;123(5):1047–1054. doi: 10.1016/j.jaci.2009.02.026
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu K, Chen J, et al. Predictive values of serum IL-33 and sST2 in Endotypes and postoperative recurrence of chronic rhinosinusitis with nasal polyps. Mediators Inflamm. 2022;2022:9155080. doi: 10.1155/2022/9155080
   PubMed Web of Science ®Google Scholar
• Lam M, Hull L, Imrie A, et al. Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis. Am J Rhinol Allergy. 2015 May;29(3):175–181. doi: 10.2500/ajra.2015.29.4176
   PubMed Web of Science ®Google Scholar
• Liao B, Cao PP, Zeng M, et al. Interaction of thymic stromal lymphopoietin, IL-33, and their receptors in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps. Allergy. 2015 Sep;70(9):1169–1180. doi: 10.1111/all.12667
   PubMed Web of Science ®Google Scholar
• Kim DK, Jin HR, Eun KM, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017 Jul;72(7):635–645. doi: 10.1136/thoraxjnl-2016-208772
   PubMed Web of Science ®Google Scholar
• Ozturan A, Eyigor H, Eyigor M, et al. The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps. Eur Arch Otorhinolaryngol. 2017 Jan;274(1):283–288. doi: 10.1007/s00405-016-4260-6
   PubMed Web of Science ®Google Scholar
• Baba S, Kondo K, Kanaya K, et al. Expression of IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2014 Apr;124(4):E115–22. doi: 10.1002/lary.24462
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov [internet]. Bethesda (MD) United States: National Library of Medicine. [updated 2022 May 19; cited 2023 Oct 8]. Available from: https://clinicaltrials.gov/study/NCT02743871
   Google Scholar
• Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790–798. doi: 10.1016/j.jaci.2021.03.044
   PubMed Web of Science ®Google Scholar
• Maurer M, Cheung DS, Theess W, et al. Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. J Allergy Clin Immunol. 2022 Dec;150(6):1517–1524. doi: 10.1016/j.jaci.2022.08.015
   PubMed Web of Science ®Google Scholar
• Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014 Oct;14(10):653–666. doi: 10.1038/nri3737
   PubMed Web of Science ®Google Scholar
• Schleimer RP, Schnaar RL, Bochner BS. Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression. Curr Opin Allergy Clin Immunol. 2016 Feb;16(1):24–30. doi: 10.1097/ACI.0000000000000234
   PubMed Web of Science ®Google Scholar
• Yokoi H, Choi OH, Hubbard W, et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol. 2008 Feb;121(2):499–505 e1. doi: 10.1016/j.jaci.2007.10.004
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gil A, Li TA, Porell RN, et al. Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8. J Allergy Clin Immunol. 2021 Apr;147(4):1442–1452. doi: 10.1016/j.jaci.2020.08.001
   PubMed Web of Science ®Google Scholar
• Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2022 Apr;149(4):1286–1295. doi: 10.1016/j.jaci.2021.09.009
   PubMedGoogle Scholar
• Xu X, Reitsma S, Wang Y, et al. Highlights in the advances of chronic rhinosinusitis. Allergy. 2021 Nov;76(11):3349–3358. doi: 10.1111/all.14892
   PubMed Web of Science ®Google Scholar
• Kato A, Peters AT, Stevens WW, et al. Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy. 2022 Mar;77(3):812–826. doi: 10.1111/all.15074
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020 Apr;124(4):326–332. doi: 10.1016/j.anai.2019.12.001
   PubMed Web of Science ®Google Scholar
• Yan B, Zhang L. Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge. Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):827–830.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, James LK. Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps? Lancet Respir Med. 2021 Oct;9(10):e97. doi: 10.1016/S2213-2600(21)00223-X
   PubMed Web of Science ®Google Scholar